SAGE meetings agenda search
Report from the IVB Department: 3 Key issues: (i) sustaining the momentum generated by the DoV/GVAP, (ii) ensuring effort to effectively support country implementation are sufficient and (iii) identifying areas for more effective coordination and collaboration between WHO and its partners.
Report from the GAVI Alliance: update on recent Board decisions, key elements under consideration for GAVI's future strategy, its poly review pipeline, and plans for replenishment of funds.
Report from the Global Advisory Committee on Vaccine Safety (GAVCS).
Immunization supply chain: review of a deeper analysis from the approximately 70 countries that have undergone EVM assessments to date.
Varicella and herpes zoster vaccines: review of global prevalence and burden of disease.
Human papilloma virus vaccines.
Pertussis vaccines: presentation of Pertussis working group's (established in 2012) report.
Non-specific effects of vaccines on childhood mortality: review of protocols for 2 commissioned independent systematic reviews.
Integration of immunization and child health services.
Report from GAVI Alliance: summary on the Alliance's mid-term review, programmatic and policy updates, and outline of GAVI's next vaccine investment strategy and plans for finalizing GAVI's strategy for 2016-2020.
Report form other advisory committees: IPAC, GACVS, and IVIR-AC.
Vaccination of pregnant and lactating women: GACVS’s comprehensive review of the evidence on safety of vaccination during pregnancy.
Decade of Vaccines (DoV) Global Vaccine Action Plan (GVAP) implementation monitoring: progress report 2013.
Pandemic and interpandemic influenza vaccines.
Measles and rubella elimination.
Immunization supply chains: key challenges impacting national immunization programmes.
Strategic review of the global sentinel hospital surveillance networks for invasive bacterial vaccine preventable disease (IB-VPD) and rotavirus (RV).
Report from IVB: focused on the scale up of immunization services required to reach the GVAP goal of 90% national coverage with 3 doses of DTP3 in all countries by 2015.
Report from the WHO Department of Immunization, Vaccines and Biologicals focused on: (i) the Global Vaccine Action Plan (GVAP) roll-out; (ii) the strengthening of routine immunization and efforts to integrate immunization and other child health interventions; and (iii) the changing epidemiology of measles.
Report from the GAVI Alliance: update on: (i) the processes and timelines for developing the next Vaccine Investment Strategy (for the period 2015–2020) beyond existing commitments, (ii) the preliminary Board discussions regarding GAVI’s potential role in supporting the GPEI, including supporting inactivated polio vaccine (IPV) introduction and potential innovative financing instruments for mobilizing resources, and (iii) the preparations for the next GAVI replenishment round in 2014.
Report from the Global Advisory Committee on Vaccine Safety (GACVS) : A report of the December 2012 GACVS meeting was presented.
Report from the Immunization Practice Advisory Committee (IPAC): A report of the April 2013 IPAC meeting was presented.
Dengue vaccines: epidemiology; review of the results of the Phase IIb trial of the lead vaccine candidate, a tetravalent live attenuated vaccine and other considerations.
Polio eradication: progress and challenges.
Yellow fever vaccination: A report was presented from the SAGE working group on yellow fever (YF) vaccines.
Non-specific effects of vaccines on mortality: established a working group to review data on non-specific effects and consider whether current evidence is sufficient to merit adjustments in policy recommendations, or may warrant further scientific investigation and if so, to outline a path towards obtaining unequivocal evidence that would inform future robust, evidence-based adjustments in immunization policies, if warranted.
Haemophilus influenza type b (Hib) immunization schedules.
Report from the WHO Department of Immunization, Vaccines and Biologicals.
Report from the GAVI Alliance.
Report from the Global Advisory Committee on Vaccine Safety (GACVS).
Expert Committee on Biological Standardization (ECBS).
Immunization Practices Advisory Committee (IPAC).
Immunization and Vaccine Related Implementation Research Advisory Committee (IVIR).
Decade of Vaccines Global Vaccine Action Plan (GVAP): an overview of progress in putting the GVAP into operation since the 65th World Health Assembly (WHA) in May 2012. SAGE made the following recommendations on the proposed Monitoring & Evaluation/Accountability Framework (Monitoring indicators; Monitoring commitments and resources and updating the cost and impact analysis for the Decade of Vaccines).
Optimization of Haemophilus influenzae type b (Hib) conjugate vaccine schedules.
Measles and rubella.
Vaccination in humanitarian emergencies.
New vaccine introduction in middle-income countries (MICs): current initiatives to address financial challenges.
Report from Director, IVB: Global report including key updates and challenges from regions.
Reports from other Advisory Committees on Immunization: Report of the Global Advisory Committee on Vaccine Safety GACVS.
Polio eradication: Global polio eradication initiative (GPEI) Emergency Action Plan 2012-13: planned corrective actions in 'off-track' countries (Pakistan, Nigeria, Afghanistan); Prioritizing emergency polio eradication activities in view of the chronic financing gap; The tOPV - bOPV switch and suggested IPV policy to complete type 2 eradication.
Seasonal influenza vaccine: Global influenza burden of disease; Influenza vaccine effectiveness; Safety of influenza vaccines; Presentation of recommendations.
Impact of introduction of new vaccines on the strengthening of immunization and health systems: Brief introduction to the session; Summary of findings from literature reviews and assessments and interviews in the context of the WHO Health System Building Blocks Framework; Review of findings and gaps in information on impact of new vaccines on immunization and health systems; Discussion: Focus on findings and evidence gaps; Principles for new vaccine introduction; A practical tool for countries, updated WHO document entitled: "Principles and Considerations for Adding a Vaccine to a National Immunization Programme”; Discussion of principles and specific sections of the updated WHO document.
Vaccination in humanitarian emergencies: Brief introduction of the process that is being followed for the development of the framework; Literature review of vaccination experience in previous humanitarian emergencies /Existing recommendations and guidance; Ethical issues surrounding use of vaccines in emergency settings; Vaccination in acute humanitarian emergencies: a framework for decision-making.
Rotavirus vaccines schedules: Optimizing rotavirus schedules: what are the key questions for today's session?; Rotavirus vaccine effectiveness after 2 or 3 doses and risk of Intussusception after rotavirus vaccination; Rotavirus vaccination: tailoring the immunization schedule to the local epidemiology and operational realities; Benefits of mortality reduction versus risk of fatal intussusception; Overview of major conclusions from the ad hoc group of experts.
Use of hepatitis A vaccines: Evidence and recommendations on the flexibility of a booster dose of inactivated hepatitis A vaccine with focus on long-term protection achieved by single dose administration: Impact and monitoring the impact of single dose hepatitis A vaccine use in Argentina; Process of evidence and data collection and overview of evidence obtained including GRADE tables; Draft recommendations for flexible use of inactivated hepatitis A vaccine booster dose.
Report from the GAVI Alliance Secretariat.
Information on vaccines for an Intergovernmental Negotiating Committee on Mercury: Outcomes from a WHO Informal Consultation (3-4 April) on further guidance on vaccines in preparation for the fourth Intergovernmental Negotiating Committee (INC4); Perspectives from stakeholders countries; Manufacturers perspective; Potential guidance to countries on vaccines for the mercury-treaty negotiations.
Opening session by Margaret Chan, WHO/DG and Helen Rees, Chair of SAGE.
Decade of Vaccines Consultation: discussion and decision on the Global Vaccine Action Plan (GVAP) revised version prior to the document being submitted to the WHA.
Feedback obtained from the consultation process, DoVC progress update and January 2012 Executive Board meeting.
Revised Global Vaccine Action Plan (GVAP): DoV Guiding Principles and Goals; The Six DoV Outcomes.
Benefits, costs and funding: Health and Economic Benefits; Costing and Financing; R&D Costs.
The accountability framework: DoV/GVAP Indicators; Roles and Responsibilities and Accountability Processes
Global Polio eradication: Emergency Action Plan (context & major elements); Lessons from India; Intensification of New Tactic to address Chronic Programme Gaps; Recommendation of Strategy Review Meeting; Brief Orientation from the Polio Working Group on Policy Issues to be brought to SAGE at the April meeting.
Report from Director, IVB: Global report including key updates and challenges from regions.
Report from the GAVI Alliance Secretariat.
Reports from other Advisory Committees on Immunization: GACVS, IPAC, QUIVER, ECBS.
Decade of Vaccines.
Global Vaccine Safety Blueprint: Blueprint development process; Blueprint vision and strategic goals, questions to SAGE.
Monitoring national immunization coverage: WHO and UNICEF estimates of national immunization coverage: Overview of data, methods and processes used for the WHO and UNICEF estimates of national immunization coverage; Activities to improve immunization data quality in the American region.
Reinforcing surveillance: Introduction to VPD surveillance coordinated by WHO; Progress and challenges with surveillance for rotavirus diarrhoea and invasive bacterial vaccine-preventable diseases (IB-VPD); Regional perspective on improving the quality of IB-VPD surveillance; Proposed next steps for improving quality of IB-VPD surveillance.
Review of serotype replacement in the setting of 7-valent pneumococcal conjugate vaccine (PCV7) use and implications for the PCV10/PCV13 era: Methods & results for serotype replacement; Methods & results for use of surveillance systems to evaluate PCV impact; Summary of key findings with proposed next steps and recommendations.
Optimizing immunization schedules for conjugate pneumococcal Vaccines: Developing an approach to assess evidence on immunization schedules: the experience with PCV vaccines; What is the available evidence on PCV schedule(s) for children in various areas of the world?.
Polio eradication: Is it time for a new 'polio endgame': context, options & implications for SAGE: Operational priorities through mid-2012 for wild poliovirus eradication; Could a combination of OPV & IPV accelerate wild poliovirus eradication?.
Tuberculosis vaccines: The value of new tuberculosis (TB) vaccines in reducing burden of disease; TB Vaccine Pipeline, Clinical Trials and Challenges; Critical activities and strategies for advancing and introducing TB vaccines; Planned WHO activities related to TB vaccine development.
Hepatitis A: Evidence and recommandations on use of hepatitis A vaccine : update by the SAGE hepatitis A working group.
Report from IVB Director.
Regional priorities, major policy and implementation issues: reports from AFR, EMR, SEAR.
Report from the GAVI Alliance secretariat.
Report from the Advisory Committee of the Initiative for Vaccine Research (IVAC).
Report of the Global Advisory Committee on Vaccine Safety (GACVS).
Pandemic and seasonal influenza vaccines:International Health Regulations Review Committee (IHR): conclusions and recommendations; H1N1 update: - use of deployed vaccine - epidemiology; SAGE Working Group on influenza vaccines and immunization:Update on process.
Tick-borne encephalitis: context and process; Disease epidemiology & burden of disease; Vaccine effectiveness and safety; Draft recommendations on the use of tick-borne encephalitis vaccines.
Meningococcal meningitis vaccines:Update on the epidemiology of meningococcal disease; Availability, safety and effectiveness of conjugated meningococcal A and C vaccines; Draft recommendations on the use of meningococcal vaccines.
Rubella vaccination: Report from the Working Group; Modelling the minimum coverage required to avoid an increased risk of CRS; Draft recommendations on the introduction of rubella vaccine and use of combined MR vaccine.
Polio eradication: Outcomes from the Independent Monitoring Board for the Global Polio Eradication Initiative; New breakthroughs in assuring affordable IPV options for low-income countries in the post-eradication era; SAGE IPV Working Group: potential pre-requisites if cessation of type-2 oral poliovirus vaccine is to be considered before global certification.
Update on evidence-based review process and GRADing of quality of scientific evidence: Update from the SAGE discussion group.
Cholera vaccine: feed-back on implementation of SAGE recommendations: Use of cholera vaccine in countries: progress and challenges; Challenges of use of cholera vaccine in Haiti; Investment case for accelerated introduction of cholera vaccines.
Report form the department: recent licensure of the meningococcal A conjugate vaccine MenAfriVac; issues related to global coverage with DTP3; coverage of Hib; update on developments of the DoV.
Report from the GAVI Alliance.
Regional reports: PAHO, EURO, WPRO.
Reports from other advisory committees: ECBS, GACVS, IPAC, QUIVER.
Seasonal and pandemic influenza: update on H1N1 2009 vaccine pharmacovigilence and deployment.
Polio eradication: update on the Global Polio Eradication Initiative's strategic plan for 2010-2012, the CDC most recent quarterly risk assessment on polio surveillance and SIAs, and a report from SAGE's working group on inactivated poliovirus vaccine (IPV).
Feasibility of measles eradication: review the report and recommendations from the July 2010 Global Technical Consultation to Assess the feasibility of Measles eradication. SAGE concluded that measles can and should be eradicated. A goal for measles eradication should be established with a proposed target date based on measurable progress made towards existing goals and targets. The eradication of measles represents unique disease control and developmental opportunities, and should be carried out in the context of strengthening routine immunization programmes.
Typhoid vaccines: feedback on regional implementation of SAGE recommendations.
Optimizing immunization schedules: update on the Optimizing Immunization Schedules project.
Lover-middle-income countries: sustainable adoption and financing for new vaccines.
Accessibility of affordable vaccines: gaps and WHO's role in supporting emerging manufacturers. SAGE suggested that a more developed perspective be presented at a future SAGE meeting.
The epidemiology of unimmunized children and gender-related issues: SAGE emphasized the importance of implementing
Strategies such as Reach Every District to enhance overall coverage and reduce differences in immunization coverage among boys and girls and other inequities where these exist.
Report from the Director, IVB on progress made in implementing the previous recommendations of SAGE.
Report from the GAVI Alliance on key decisions from the board meeting held in November 2009, including the adoption of a new eligibility policy for funding, the recent launch of the Advanced Market Commitments (AMC) for the supply of pneumococcal conjugate vaccines, and on priorities for 2010.
Regional reports : AFRO focused on plans to (i) reduce the number of unimmunized children, (ii) consolidate gains made in reducing mortality from measles,and (iii) interrupt polio transmission; EMRO focused on (i) progress made by the routine immunization programme to improve performance and efforts made to increase access to vaccines in countries affected by conflict, and (ii) initiatives to strengthen the capacity of national immunization technical advisory groups and to organize a regional immunization week; SEARO highlighted the challenges caused by adverse events following immunization(AEFI), the impact of these, and steps being taken to address them.
Report from the Global Advisory Committee on Vaccine Safety: an update of the December 2009 meeting of GACVS and a report on a special GACVS teleconference held on 25 March 2010.
Revision of prequalification procedure for vaccines: SAGE was briefed on the revision process and provided input on the procedure and proposals to define the programmatic suitability of candidate vaccines for prequalification.
Impact of the introduction of new vaccines on immunization and health systems: SAGE endorsed the importance of gaining a better understanding of the potential positive and negative impacts of the introduction of new vaccines on immunization programmes and broader health systems.
Pertussis vaccines: The working group on pertussis vaccines presented SAGE with evidence on the safety and impact of providing pertussis vaccination beyond the primary series.
HIV vaccine trial: The results of the RV144 HIV vaccine trial, conducted in Thailand, were presented to SAGE by the principal investigators.
Influenza vaccines SAGE was updated on the epidemiology of influenza A(H5N1) and pandemic influenza A(H1N1) 2009 viruses.
Grading and review of evidence: feedback from a SAGE discussion group; concerns and encouragements to improve the process.
Global Polio Eradication Initiative: SAGE received reports on the epidemiology of poliovirus, progress made in eradication efforts, risks if implementation of eradication strategies are incomplete, the initiative's new strategic plan for 2010-2012, the proposed process for monitoring the plan, and the draft WHO position paper on routine polio vaccination.